134 related articles for article (PubMed ID: 19308757)
1. Persistent neuropathy after treatment with cisplatin and oxaliplatin.
Brouwers EE; Huitema AD; Boogerd W; Beijnen JH; Schellens JH
Acta Oncol; 2009; 48(6):832-41. PubMed ID: 19308757
[TBL] [Abstract][Full Text] [Related]
2. A pilot study on the relation between cisplatin neuropathy and vitamin E.
Bove L; Picardo M; Maresca V; Jandolo B; Pace A
J Exp Clin Cancer Res; 2001 Jun; 20(2):277-80. PubMed ID: 11484987
[TBL] [Abstract][Full Text] [Related]
3. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
8. The effect of diabetes on oxaliplatin-induced peripheral neuropathy.
Uwah AN; Ackler J; Leighton JC; Pomerantz S; Tester W
Clin Colorectal Cancer; 2012 Dec; 11(4):275-9. PubMed ID: 22682776
[TBL] [Abstract][Full Text] [Related]
9. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
10. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
Tofthagen C; McAllister RD; McMillan SC
Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
[TBL] [Abstract][Full Text] [Related]
11. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
16. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
[No Abstract] [Full Text] [Related]
17. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T
Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767
[TBL] [Abstract][Full Text] [Related]
18. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
20. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]